Category: imidazoles-derivatives

Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry was written by Sun, Lu-Ning;Zhang, Ye;Yang, Yu-Qing;Shen, Ye;Ying, Yu-Wen;Su, Yu-Wen;Zhang, Xue-Hui;Liu, Yun;Huang, Xu;Wang, Yong-Qing. And the article was included in Journal of Separation Science in 2020.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Proton pump inhibitors, including omeprazole, rabeprazole, lansoprazole, and pantoprazole, achieved simultaneous enantioselective determination in the human plasma by chiral liquid chromatog.-tandem mass spectrometry. The four corresponding stable isotope-labeled proton pump inhibitors were adopted as the internal standards Each enantiomer and the internal standards were extracted with acetonitrile containing 0.1% ammonia, then separated with a Chiralpak IC column (5渭m, 4.6 mm 脳 150 mm) within 10 min. The mobile phase was composed of acetonitrile-ammonium acetate (10 mM) containing 0.2% acetic acid (50:50, volume/volume). To quantify all enantiomers, an API 4000 tandem mass spectrometer was used, and multiple reaction monitoring transitions were performed on m/z 360.1鈫?42.1, 384.1鈫?00.1, 370.1鈫?52.1, and 346.1鈫?98.1, resp. No significant matrix effect was observed for all analytes. The calibration curve for all enantiomers were linear from 1.25 to 2500 ng/mL. The precisions for intra- and inter-run were < 14.2%, and the accuracy fell in the interval of -5.3 to 8.1%. Stability of samples was confirmed under the storage and processing conditions. The developed method was also suitable for separation and determination of ilaprazole enantiomers. The validated method combining the equilibrium dialysis method was applied to the protein binding ratio studies of four pairs proton pump inhibitor enantiomers in human plasma. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors was written by Schueller, Olivier;Willson, Ashley;Singh, Nand;Lohmer, Lauren;Alabanza, Anginelle;Patel, Jeegar. And the article was included in Clinical Pharmacology in Drug Development in 2022.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Belumosudil is a selective Rho-associated protein kinase 2 inhibitor. Inhibition of Rho-associated protein kinase 2 has emerged as a promising treatment for chronic graft-vs.-host disease by restoring immune homeostasis and reducing fibrosis. In vitro assessments have suggested that metabolism of belumosudil is primarily dependent on cytochrome P 450 (CYP) 3A4 activity and that the solubility of belumosudil is pH dependent. As such, this 2-part clin. drug-drug interaction study was conducted to assess the effect of itraconazole (a strong CYP3A4 inhibitor), rifampicin (a strong CYP3A4 inducer), rabeprazole, and omeprazole (both proton pump inhibitors) on the pharmacokinetics of belumosudil. No clin. relevant change in belumosudil exposure was observed following a 200-mg single oral dose of belumosudil with itraconazole; however, exposure of main metabolite, KD025m2, was decreased. Consistent with the proposed metabolic pathway of belumosudil, the strong CYP3A4 inducer rifampicin significantly decreased exposure of belumosudil and KD025m2 and increased KD025m1 exposure. When a 200-mg single oral dose of belumosudil was coadministered with both rabeprazole and omeprazole, parent and metabolite exposures were largely reduced, suggesting that belumosudil dosage should be increased when given with PPIs. Administration of belumosudil with and without perpetrator drugs was safe, and no notable adverse events were reported. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

POD24 in follicular lymphoma: time to be “wise” was written by Leonard, John P.. And the article was included in Blood in 2022.Application of 16506-27-7 The following contents are mentioned in the article:

A polemic in response to Casulo et al is given. The present article describes about focusing on an important problem in follicular lymphoma. FL is the most common form of indolent non-Hodgkin lymphoma and the second most common type overall. After decades of minimal progress with chemotherapy-based treatments, availability of the anti-CD20 antibody rituximab (R) in 1997 led to significant improvements in overall survival. Initial management strategies for patients with advanced-stage disease now include observation for patients with asymptomatic, low tumor burden disease, whereas those requiring therapy may receive rituximab alone. Most patients receive rituximab (or the anti-CD20 obinutuzumab) in combination with chemotherapy such as bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), or cyclophosphamide/vincristine/prednisone, which are sometimes followed by anti-CD20 antibody maintenance. Patients typically respond well to initial therapy, but relapse is expected within several years. Prognostic tools have been developed to predict outcomes, including the clin. Follicular Lymphoma International Prognostic Index (FLIPI)3 and a clinicogenetic risk model (m7-FLIPI). However, they are of limited value in choice of treatment, which is primarily driven by physician judgment and patient preferences rather than data demonstrating that one regimen is better than another for specific situations. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

An unexpected case of Borrelia garinii liver infection was written by Duffau, Pierre;Korbi, Skander;Guillotin, Vivien;Talagrand-Reboul, Emilie;Menard, Armelle;Peuchant, Olivia. And the article was included in Annals of Clinical Microbiology and Antimicrobials in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Lyme borreliosis is the most prevalent arthropod-borne infection in the Northern Hemisphere. In Europe, Borrelia afzelii is predominantly involved in cutaneous manifestations, Borrelia garinii and Borrelia bavariensis in neurol. manifestations, and Borrelia burgdorferi sensu stricto in articular ones. Liver impairement is not classical in Lyme borreliosis. Diagnosis is currently mainly based on serol. testing, and is challenging in immunocompromised patients. We report the first case of B. garinii infection revealed by liver involvement in an immunocompromised man. A 73-yr-old man with marginal zone lymphoma, treated with bendamustine and rituximab, developed intermittent fever and inflammatory syndrome. Microbial investigations were all neg. and FDG-PET showed complete remission of the lymphoma. Three months later, liver biopsy was performed and histol. revealed spirochetes-like bacteria. Microbial diagnosis was performed by 16S rDNA sequencing, flagellin (flaB) gene sequencing and multi-locus sequence typing and identified B. garinii. The patient recovered successfully after a three weeks course of antibiotics. Diagnosis was challenging because Borrelia hepatic involvement is unusual and no erythema migrans nor tick bite were notified. This case highlights that unexplained fever and inflammatory syndrome in immunocompromised patients warrants specific investigations to identify bacteria such as spirochetes. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Interfacial tension of crude oil-water system with imidazolium and lactam-based ionic liquids and their evaluation for enhanced oil recovery under high saline environment was written by Sakthivel, Sivabalan;Velusamy, Sugirtha;Nair, Vishnu Chandrasekharan;Sharma, Tushar;Sangwai, Jitendra S.. And the article was included in Fuel in 2017.Formula: C10H20N2O4S The following contents are mentioned in the article:

Matured reservoirs are being targeted for enhanced oil recovery (EOR) operations in the hope to recover the residual oil that remains trapped within the porous media. Chem. enhanced oil recovery is one of the successful oil recovery methods which is being employed for the recovery of the residual oil. Many of the conventional chems. fail to perform under high temperature and high saline reservoir conditions. These situations lead to the search for alternate flooding techniques which could efficiently produce the crude oil to the surface. The present work investigates a possible solution for the recovery of trapped crude oil using lactam and imidazolium based ionic liquids (ILs) specifically targeted towards recovery in high saline environment. Initially, the interfacial tension of the crude oil-water system has been investigated using various chem. agents, such as sodium dodecyl sulfate (SDS), and six different ILs at varying high saline concentrations as a function of temperature (283.15-353.15 K). Subsequently, flooding experiments with only polymer, only SDS, only IL, SDS + polymer and IL + polymer at zero and high saline conditions were performed. It was observed that the IL + polymer flood performed very well in both zero and high salinity conditions as compared to all other flooding systems. The present investigation also portrays an intuition on the evaluation of ILs based on their alkyl chain length. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Formula: C10H20N2O4S).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Formula: C10H20N2O4S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Two-step screening method to identify 伪-synuclein aggregation inhibitors for Parkinson’s disease was written by Hideshima, Makoto;Kimura, Yasuyoshi;Aguirre, Cesar;Kakuda, Keita;Takeuchi, Toshihide;Choong, Chi-Jing;Doi, Junko;Nabekura, Kei;Yamaguchi, Keiichi;Nakajima, Kichitaro;Baba, Kousuke;Nagano, Seiichi;Goto, Yuji;Nagai, Yoshitaka;Mochizuki, Hideki;Ikenaka, Kensuke. And the article was included in Scientific Reports in 2022.Reference of 117976-90-6 The following contents are mentioned in the article:

Parkinson’s disease is a neurodegenerative disease characterized by the formation of neuronal inclusions of 伪-synuclein in patient brains. As the disease progresses, toxic 伪-synuclein aggregates transmit throughout the nervous system. No effective disease-modifying therapy has been established, and preventing 伪-synuclein aggregation is thought to be one of the most promising approaches to ameliorate the disease. In this study, we performed a two-step screening using the thioflavin T assay and a cell-based assay to identify 伪-synuclein aggregation inhibitors. The first screening, thioflavin T assay, allowed the identification of 30 mols., among a total of 1262 FDA-approved small compounds, which showed inhibitory effects on 伪-synuclein fibrilization. In the second screening, a cell-based aggregation assay, seven out of these 30 candidates were found to prevent 伪-synuclein aggregation without causing substantial toxicity. Of the seven final candidates, tannic acid was the most promising compound The robustness of our screening method was validated by a primary neuronal cell model and a Caenorhabditis elegans model, which demonstrated the effect of tannic acid against 伪-synuclein aggregation. In conclusion, our two-step screening system is a powerful method for the identification of 伪-synuclein aggregation inhibitors, and tannic acid is a promising candidate as a disease-modifying drug for Parkinson’s disease. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Reference of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant was written by Wang, Yi;Wang, Tingyu;Yu, Ying;Wang, Qi;Yan, Yuting;Li, Ru;Sun, Qi;Xiong, Wenjie;Rui, Lyu;Yu, Zhen;Liu, Wei;Sui, Weiwei;Huang, Wenyang;Wang, Huijun;Li, Chengwen;Wang, Jun;Zou, Dehui;An, Gang;Wang, Jianxiang;Qiu, Lugui;Yi, Shuhua. And the article was included in Annals of Hematology in 2022.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Both characteristics and optimal treatment strategy for hairy cell leukemia-variant (HCL-v) remain elusive due to its rarity. We retrospectively analyzed the clin. features of HCL-v and the efficacy of first-line treatment options in a large Chinese cohort. In this study, we recruited 33 HCL-v patients (23 males and 10 females) with a median age of 59 years (range, 34-79 years). The chief complaints included abdominal mass and relative signs (67%) and abnormal complete blood count (27%). Immunophenotyping showed monoclonal B-cells pos. for pan B-cell antigens and CD11c, weakly pos. for CD103 and CD200, while neg. for CD5, CD10, CD25, CD123, and annexin A1. No BRAF V600E mutation was detected, but TP53 abnormality was recurrent. Treatment choices included interferon-伪 (IFN-伪) in 11 patients, chlorambucil (CLB) in 5 patients, single purine nucleoside analogs (PNA) in 3 patients, PNA plus rituximab (PNA + R) in 9 patients, and others in 3 patients. Four patients who received IFN-伪 or CLB treatment also underwent splenectomy. Patients who received PNA + R had a higher complete response rate (88% vs. 5%, P < 0.001) and longer progression-free survival (PFS, 3-yr PFS rate 42% [95% CI 1-84] vs. 16% [95% CI 3-40], P = 0.042) than those who received other regimens. Overall, HCL-v is an indolent lymphoma with unique characteristics. The PNA + R regimen is the preferred choice in the first-line treatment for HCL-v. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A series of hybrids with a framework constructed from {-SiW₁₁-Ln-SiW₁₁-}_n chains and {Cu/bimpy} ribbons was written by Zhou, Wanli;Zhang, Zheyu;Peng, Jun;Wang, Xiang;Shi, Zhenyu;Li, Guangzhe. And the article was included in CrystEngComm in 2014.Synthetic Route of C11H9N5 The following contents are mentioned in the article:

This paper reports the preparation and x-ray single crystal structures of five organic-inorganic hybrid compounds with 3D framework, [Cu_2.5(bimpy)₂(H₂O)₂][Ln(H₂O)₃(伪-SiW₁₁O₃₉)]路xH₂O [Ln = Eu^III and x = 3.5 for (1), Ln = Sm^III and x = 2.5 for (2), Ln = Ho^III and x = 3.5 for (3), Ln = Y^III and x = 3.5 for (4), Ln = Ce^III and x = 3 for (5)] (bimpy = 3,5-bis(1-imidazolyl)pyridine). Compounds 1–5 are isostructural, showing a 3D framework featured by {-SiW₁₁-Ln-SiW₁₁-}_n inorganic chains and {Cu/bimpy} metal-organic ribbons stemmed from Cu²⁺ ions and bimpy ligands. The adjacent {Cu/bimpy} ribbons are connected by two antiparallel {-SiW₁₁-Eu-SiW₁₁-}_n chains to create a 2D layer structure, which is extended to a (3,4,4,4,6)-connected 3D framework with (4路7²)(4路6路7³路8)(4²路5³路7)(4²路7²路9²)(4²路5²路6⁷路8³路10) topol. through the Cu-O covalent bonds. The magnetic and electrochem. properties of compounds 1 and 2 have been studied. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Synthetic Route of C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Chemotherapy after PD -1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics was written by Calabretta, Eleonora;Guidetti, Anna;Ricci, Francesca;Di Trani, Martina;Monfrini, Chiara;Magagnoli, Massimo;Bramanti, Stefania;Maspero, Davide;Morello, Lucia;Merli, Michele;Di Rocco, Alice;Graudenzi, Alex;Derenzini, Enrico;Antoniotti, Marco;Rossi, Davide;Corradini, Paolo;Santoro, Armando;Carlo-Stella, Carmelo. And the article was included in British Journal of Haematology in 2022.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

Summary : Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long-term responses are uncommon, and one-third of patients are refractory. Several reports have suggested that treatment with CPIs may re-sensitize patients to chemotherapy, however there is no consensus on the optimal chemotherapy regimen and subsequent consolidation strategy. In this retrospective study we analyzed the response to rechallenge with chemotherapy after CPI failure. Furthermore, we exploratively characterized the clonal evolution profile of a small sample of patients (n = 5) by employing the CALDER approach. Among the 28 patients included in the study, 17 (71%) were primary refractory and 26 (92%) were refractory to the last chemotherapy prior to CPIs. Following rechallenge with chemotherapy, response was recorded in 23 (82%) patients experiencing complete remission and 3 (11%) patients experiencing partial remission. The tumor evolution of the patients inferred by CALDER seemingly occurred prior to the first cycle of therapy and was characterized either by linear or branching evolution patterns. Twenty-five patients proceeded to allogeneic stem cell transplantation. At a median follow-up of 21 mo, median PFS and OS were not reached. In conclusion, patients who fail CPIs can be effectively rescued by salvage chemotherapy and bridged to allo-SCT/auto-SCT. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Stem cell transplant for mantle cell lymphoma in Taiwan was written by Wang, Yu-Hung;Hsieh, Ching-Yun;Hsiao, Liang-Tsai;Lin, Tung-Liang;Liu, Yi-Chang;Yao, Ming;Tan, Tran-Der;Ko, Bor-Sheng. And the article was included in Scientific Reports in 2022.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Mantle cell lymphoma (MCL) is a B-cell lymphoma featuring an aggressive course and a progressive relapsing pattern. International guidelines recommend early consolidative autologous stem cell transplant (auto-SCT) for eligible patients while reserving allogeneic SCT (allo-SCT) as therapy for refractory cases. Since data describing the implementation of transplants in the Asian population with MCL are limited, we aimed to analyze post-SCT outcomes of 99 MCL patients from the Taiwan Bone Marrow Transplant Registry database. The median age was 56 years, and 11% of the patients had blastoid variant MCL. Ninety-four patients received auto-SCT, while 13 patients received allo-SCT, eight of which received allo-SCT after failing auto-SCT. Before auto-SCT, 52% of the patients were in their first complete remission (CR1). Overall, 37 patients (39%) relapsed after auto-SCT. The median post-auto-SCT progression-free survival and overall survival (OS) were 43.6 mo and not reached, resp. Blastoid variant MCL, transplant not received in CR1, and disease progression within 12 mo post-auto-SCT independently predicted inferior OS in multivariable anal. The median post-allo-SCT OS was 74 mo. Two patients (15%) died of MCL recurrence post-allo-SCT. Three patients with refractory diseases were salvaged with ibrutinib or venetoclax to allo-SCT. Treatment strategies incorporating novel agents warrant further optimization. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem